As we near the end of 2022, its worth taking a look back at year and understanding the behaviors that leaders might avoid or stop-doing

Drug development today is experiencing rapid changes driven by the use of data to make better decisions. The rapid changes have been accelerated by the

(Series, Part II of II) In my last post, I discussed how Big Pharma has to learn to compete with Big Tech for a healthcare

(Series, Part I of II)  Big pharma is changing. As an industry, big pharma realizes that it is no longer viable to rely on their

Note: This is a redacted case example of where Nooma supported a senior pharma leader during her transition. Frieda is a well- respected clinical operations